Financials
| 2024 Interim Results and Business Updates | Jul. 31, 2024 |
| 2023 Full Year Results and Business Updates | Feb. 28, 2024 |
| Interim Results and Business Updates | Jul. 31, 2023 |
| 2022 Full Year Results and Business Updates | Feb. 28, 2023 |
| Interim Results and Business Updates | Aug. 01, 2022 |
| Full Year Results and Business Updates | Mar. 03, 2022 |
| Interim Results and Business Updates | Jul. 28, 2021 |
Proxies
| Result of AGM | May. 10, 2024 |
| 2023 Annual Report and Notice of AGM | Apr. 08, 2024 |
| Annual General Meeting Poll Results | May. 12, 2023 |
| 2022 Annual Report and Notice of AGM | Apr. 11, 2023 |
| Annual General Meeting Poll Results | Apr. 27, 2022 |
| 2021 Annual Report and Notice of AGM | Mar. 23, 2022 |
Ownership Update
| Vesting of awards under the LTIP | Oct. 21, 2024 |
| Standard form for notification of major holdings | Aug. 22, 2024 |
| LTIP and Share Option Scheme | Aug. 06, 2024 |
| Vesting of Awards Under the LTIP | Apr. 22, 2024 |
| LTIP and Share Option Scheme | Mar. 14, 2024 |
| Vesting of awards under the LTIP | Mar. 05, 2024 |
| Vesting of awards under the LTIP | Oct. 24, 2023 |
Announcements
| HUTCHMED to Receive Milestone Payment from Takeda | Dec. 13, 2024 |
| Breakthrough Therapy Designation in China | Dec. 12, 2024 |
| HUTCHMED and Innovent Announce ELUNATE Approval | Dec. 03, 2024 |
| Total Voting Rights | Nov. 29, 2024 |
| Continued Inclusion of ORPATHYS in China NRDL | Nov. 28, 2024 |
| FRUZAQLA® Launched in Japan by Takeda | Nov. 22, 2024 |
| Appointment of Independent Non-executive Director | Nov. 20, 2024 |